{"id":"ee818856a410","type":"article","url":"https://hartvaat.nl/2026/02/01/semaglutide-en-ziekenhuisopnames-bij-obesitas-met-hart-en-vaatziekten/","title":"Semaglutide en ziekenhuisopnames bij obesitas met hart- en vaatziekten","title_en":"Semaglutide and Hospitalizations in Patients With Obesity and Established Cardiovascular Disease","category":"preventie","category_label":"Preventie","professions":["apotheker","cardioloog","internist"],"tags":["flow-trial","select-trial","semaglutide","soul-trial","step-hfpef","stride-trial"],"journal":"JAMA Cardiology","doi":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2843245","source_url":"https://doi.org/https://jamanetwork.com/journals/jamacardiology/fullarticle/2843245","authors":[],"significance":8,"published":"2026-02-01","source_date":"2026-02-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/cardiometabool/diabetes-type-1-en-hart/"],"congress":"","summary_en":"This SELECT prespecified analysis showed that semaglutide reduces total hospital admissions and length of stay in patients with obesity and established cardiovascular disease, demonstrating healthcare utilization benefits beyond cardiovascular event reduction.","created":"2026-07-03T10:25:27Z","updated":"2026-07-03T13:24:52Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Vooraf gespecificeerde analyse van de SELECT-trial naar het effect van semaglutide op het totaal aantal ziekenhuisopnames en de opnameduur bij patiënten met obesitas en bewezen cardiovasculaire ziekte.","abstract_original":"This prespecified exploratory analysis of the SELECT randomized clinical trial determines the impact of semaglutide on total hospital admissions and duration of hospital stay."}